Capecitabine Plus Bevacizumab for Cardiac Metastasis of Sigmoid Colon Cancer: Case Report and Literature Review

In Vivo. 2020 Nov-Dec;34(6):3413-3419. doi: 10.21873/invivo.12180.

Abstract

Background/aim: Right ventricular cardiac metastasis from colorectal cancer (CRC) is rare and clinically silent. There is no standardised treatment. To date, only twelve cases have been reported in the literature. This is a case report and literature review of right ventricular cardiac metastasis from CRC.

Case report: A 75-year-old woman with a history of CRC treated with sigmoidectomy followed by liver and lung metastasectomy presented with a right ventricle tumour. Biopsy showed metastatic adenocarcinoma not suitable for resection because multiple lung metastases coexisted. The metastases were controlled for a prolonged duration by chemotherapy with capecitabine plus bevacizumab. According to the review of 13 cases, the median age of metastatic CRC that involves the right ventricle is 71 years and the primary site is half the colon and rectum. Half of cases have non-cardiac metastases at cardiac metastasis diagnosis. Chemotherapy is more suitable than resection in cases with metastases other than heart because resection of the right ventricle has a high risk.

Conclusion: Cardiac right ventricular metastasis from CRC can be controlled by capecitabine plus bevacizumab.

Keywords: Bevacizumab; capecitabine; cardiac metastasis; colorectal cancer; right ventricle.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adenocarcinoma* / drug therapy
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bevacizumab / therapeutic use
  • Capecitabine
  • Colorectal Neoplasms* / drug therapy
  • Female
  • Humans
  • Sigmoid Neoplasms* / drug therapy
  • Sigmoid Neoplasms* / surgery

Substances

  • Bevacizumab
  • Capecitabine